BOS-371 / Boston Pharma, GSK - LARVOL DELTA

BOS-371, a monoclonal antibody against IL1RAP: Characterization in preclinical models of AML. (ASCO 2023) - "These findings demonstrate that BOS-371 binds with high affinity to IL1RAP, potently inhibits IL1 signaling and induces ADCC, leading to anti-leukemic activity in vitro and in vivo. The preclinical results support the clinical investigation of BOS-371 for the treatment of myeloid malignancies. A Phase 1 trial is currently in development."

Preclinical • Acute Myelogenous Leukemia • Chronic Myeloid Leukemia • Lung Cancer • Myelodysplastic Syndrome • Solid Tumor • FLT3 • IL1A • IL1RAP • IL6 • KIT